Please ensure Javascript is enabled for purposes of website accessibility

Why Intellia Therapeutics Was a Winner on Wednesday

By Eric Volkman - Jun 30, 2021 at 4:20PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company is about to fatten its coffers significantly.

What happened

Mere days after enjoying a major stock price pop, Intellia Therapeutics (NTLA -3.23%) had another good day on Wednesday. The gene-editing specialist's shares closed almost 7% higher on news of its latest capital-raising move.

So what

Intellia announced after market close on Tuesday that it is floating a public offering of nearly 4.14 million shares of its common stock. These are to be priced at $145 per share. The issue's underwriters have been granted a 30-day option to buy up to an additional 620,689 shares.

Intellia said the offering should close on or about this Friday, July 2.

A researcher studying a sample in a petri dish.

Image source: Getty Images.

In a regulatory filing, the company wrote that, "We intend to use the net proceeds from this offering to advance the clinical development of our lead programs, other pipeline candidates and the continued investment in our modular platform as well as for working capital, and other general corporate purposes."

All told, the company should earn gross proceeds of over $600 million from the issue. As of the end of March, it had approximately the same amount of cash, equivalents, and marketable securities on its books.

Now what

Intellia is a healthcare sector darling at the moment, thanks to the highly promising interim clinical trial results of its pioneering gene therapy treatment NTLA-2001 that were published last week. With the capital raise -- which, by the way, isn't overly dilutive -- the company is sensibly riding its recent popularity and share-price surge to raise some ever-needed cash.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Jefferies Financial Group Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Intellia Therapeutics Stock Quote
Intellia Therapeutics
$63.32 (-3.23%) $-2.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/08/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.